Floatz logo

Dilanubicel

Untreated Adult Acute Myeloid Leukemia

Nohla Therapeutics, Inc.Cell therapyPhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
27/ 100
Competitive Position
89/ 100

Competitive context

16 Active assets in the Untreated Adult Acute Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Daunorubicin
Wake Forest University Health Sciences
Phase 3BBB
Cytosin-Arabinosid
Wake Forest University Health Sciences
Phase 3BBB
ETOPOSIDE
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 3BBB
Mitoxantrone
Fred Hutchinson Cancer Center
Phase 2BBB
Idarubicine
University of Nebraska
Phase 3BB

View all 50 →

Same molecule, other indications

Dilanubicel is also rated in:

acute myeloid leukemia, del(5q31-q32)Dormant
CCC
Indicative ·
52 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
CCC
Indicative ·
52 / 100
View asset →
acute myeloid leukemia with 11q23 abnormalitiesDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →